Revisit Every OncLive On Air Episode From July 2025

In case you missed any, below is a recap of the episodes of OncLive On Air® that debuted in July 2025. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

In the final part of this 3-episode miniseries, part of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, sat down with Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss the challenges faced by community oncologists in accessing clinical trials for patients with metastatic colorectal cancer (mCRC), agents for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan), the promising results generated with trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin), and emerging frontline therapies for patients with mCRC.

“I’m enthusiastic [about] being able to provide our patients excellent treatments that are cutting-edge treatments,” Malla said. “Coming up, there are a lot more advances happening in this field, [one of the] key advances being targeted therapy.”

“I love your passion and energy and your guidance,” Park said to Malla. “You’re always on the cutting edge. You’re always looking at new studies, and you do a lot of research.”

FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS

In this episode of OncLive On Air, Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute in Boston, Massachusetts; and Neal Shore, MD, FACS, of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, highlighted the significance of the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), key findings from the phase 3 ARANOTE trial (NCT04736199), and how this regulatory decision may influence the future of mCSPC research.

“From a medical oncologist perspective, one of the best things about this approval is that we have been using darolutamide to treat patients with mCSPC, but we have, in most cases, been trying to do that per label, which was to use it with ADT and docetaxel, because that’s the setting that it had been studied in,” Morgans stated. “[However], with this new approval, we don’t necessarily have to use chemotherapy. For many patients, it’s offering an opportunity to get an active agent and change the trajectory of their disease, help them live longer, help them maintain their quality of life, and not have to use chemotherapy if that’s either not something that’s suitable for them or else not really recommended given their cancer status.”

“It expands the proverbial toolbox,” Shore added. “Choices are always great. We now see another important, global phase 3 trial demonstrating the value proposition of ADT, an androgen receptor pathway inhibitor, and in this case in ARANOTE, darolutamide. [We] have spent a lot of time promoting the importance of intensification for these patients so at most they should not be getting ADT monotherapy.”

ASCO 2025 Plenary — MATTERHORN

In this episode, OncLive On Air partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN trial (NCT04592913) investigating the addition of durvalumab (Imfinzi) to FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with previously untreated, resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. Hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, discussed key data and clinical implications from this trial.

“The MATTERHORN trial…met its primary end point of improving event-free survival in previously untreated gastric or GEJ adenocarcinomas that were possibly resectable,” Armstrong summarized. “The overall survival [OS] benefit is not statistically significant yet, but [data are] immature. It’s trending toward a benefit; we just need to see those data mature. This could be practice changing in the future.”

“We always care about the OS, but at least it seems to be trending in the right direction, and we’re seeing immunotherapy move up into all disease settings,” Tawagi noted.

How Enthusiasm for Science and Global Change Culminates in Wide-Reaching Opportunities to Improve Cancer Care: D. Ross Camidge, MD, PhD; and Catharine Young, PhD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Catharine Young, PhD, of the Harvard T. H. Chan School of Public Health in Boston, to discuss Young’s career journey, highlighting her previous work as the assistant director of Cancer Moonshot Policy and International Engagement in the White House Office of Science and Technology Policy in Washington, DC.

“I have spent my career utilizing science at the core of everything I do to either advance science in some capacity or to use it for the good of the world,” Young shared. “That is often either an equity piece or an innovation piece. That has led me to many amazing experiences in my career.”

“You were operating at the international level, so that’s perfect for an executive director,” Camidge commented.

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

In this episode, Justine Bruce, MD, of the University of Wisconsin Carbone Cancer Center in Madison, talked through evolving nasopharyngeal carcinoma (NPC) management strategies, including the shift from chemoradiation followed by adjuvant chemotherapy to induction chemotherapy with gemcitabine plus cisplatin, the efficacy of toripalimab-tpzi (Loqtorzi) plus chemotherapy in the first-line setting, and the importance of considering OS when determining the efficacy of nasopharyngeal cancer treatments.

“Immunotherapy has done extremely well in [many] disease types,” Bruce spotlighted. “I’m not surprised that NPC is now included.”

FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP

In this episode, Apar Kishor Ganti, MD, and Allison Cushman-Vokoun, MD, PhD, FCAP, both from the University of Nebraska Medical Center in Omaha, discussed the significance of the FDA approval of the Oncomine DX Express Test for use as a companion diagnostic for sunvozertinib (Zegfrovy) in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC) and for use in tumor profiling.

“From a clinical perspective, having a turnaround [time] of less than 24 hours will be important,” Ganti emphasized about the test. “It will decrease [patient] anxiety.”

“Some institutions prefer performing tests that have been approved by the FDA,” Cushman added. “Having a rapid test, especially when it takes longer to get specimens…helps make up for that. Having the test available will make it easier to get the testing done quickly so the patients can plan better and sooner, rather than wait.”

Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ

In this OncClub episode, Henry M. Kuerer, MD, PhD, FACS, CMQ, of The University of Texas MD Anderson Cancer Center in Houston, discussed the rationale, findings, and implications of a prospective phase 2 clinical trial (NCT02945579) that investigated the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response following neoadjuvant systemic therapy.

“In testing this new paradigm, we were fortunate that there were no recurrences,” Kreuer reported. “This is likely attributable to the efficacy of systemic therapy and radiotherapy for these patients. This is something we cannot ignore—it warrants further investigation.”

Check out the full OncClub subseries to see additional findings and insights from this research.

IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD

In this OncClub episode, Jonathan M. Gerber, MD, of the New York University Perlmutter Cancer Center in New York; and Shyam A. Patel, MD, PhD, of the UMass Memorial Medical Center in Worcester, Massachusetts, highlighted the background, findings, and clinical relevance of a study evaluating the use of immunohistochemistry (IHC) as a biomarker for early TP53 mutation identification in patients with acute myeloid leukemia and myelodysplastic syndromes.

“Intensive chemotherapy is largely ineffective, particularly in patients with high allele burdens,” Gerber explained. “Knowing a [patient’s] TP53 mutation status as early as possible allows us to divert patients into the appropriate therapies and begin transplant planning. Even a lead time of a couple of weeks can be a critical and useful window.”

“[Based on these data], we may also want to consider the technical aspects of the p53 IHC in terms of the large-scale validation of the IHC as an early surrogate for TP53 mutations,” Patel summarized.

Check out the full OncClub subseries to see additional findings and insights from this research.

European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD

In this episode, Arndt Vogel, MD, of UHN–Princess Margaret Cancer Centre in Canada, discussed the significance of the European Commission’s marketing authorization of zanidatamab-hrii (Ziihera) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer.

“The outcome with zanidatamab compared with what we have seen with chemotherapy was really good,” Vogel emphasized.

Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC

In this episode, Xavier Leleu, MD, PhD, of Hôpital La Mileterie in Poitiers, France; and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, of Cleveland Clinic in Ohio, shared key takeaways from the phase 3 IRAKLIA study (NCT05405166) evaluating the use of isatuximab-irfc (Sarclisa) plus pomalidomide and dexamethasone administered through an on-body delivery system in patients with relapsed/refractory multiple myeloma.

“Isatuximab exists as an intravenous [IV] formulation, and the IV formulation is not nice for patients,” Leleu explained. “It’s not nice for us as well, because it takes more time, and we have more patients in the outpatient clinic [as] more patients survive with myeloma. The incidence of myeloma [has] increased, but the number of patients surviving is increasing as well, because we treat myeloma much better. Altogether, we need isatuximab to be subcutaneous.”

“The adverse effect incidences were better, and the [low rate of] infusion-related reactions [IRRs] was [notable],” Faiman stated. “When you’re talking to a patient about a potential treatment option and that they might have a reaction, it’s reassuring for the patients and for the provider to know that that that they’re less likely going to have an IRR to that drug if they’re using a subcutaneous on-body device vs IV.”

Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD

In this debut episode of Cancer, Character, and Calling: The Oncologist’s Journey, Girindra Raval, MD, was joined by Jorge Cortes, MD, of the Medical College of Georgia of Augusta University. Drs Raval and Cortes discussed Dr Cortes’ career journey from Mexico City to Texas to Georgia, the range of leadership positions he has held, and how his experiences have facilitated lasting connections, both personal and professional.

“Cortes has been a visionary,” Raval said. “He’s a national and international name in leukemia, especially chronic myeloid leukemia. We have been graced with his presence here at the Georgia Cancer Center, and under his leadership, we are thriving.”

“It’s a complex but exciting time for oncology and hematology,” Cortes said of the field. “You can see the future because this progress happens faster all the time, and it’s coming to the clinic much faster. The things that happen in the laboratory now are going to be in the clinic quickly, which is good, because sure enough, there are a lot of areas where we can use better treatments.”

Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD

In this episode, Joshua K. Sabari, MD, of the Perlmutter Cancer Center in New York, New York, spotlighted the evolving use of telisotuzumab vedotin-tllv (Emrelis) in patients with c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.

“Telisotuzumab vedotin is an exciting compound,” Sabari explained. “It’s an antibody-drug conjugate with a monomethyl auristatin E payload conjugated to a c-MET antibody that targets [the] MET antigen. We just saw an FDA approval in [patients with NSCLC with] c-MET 3+ overexpression following disease progression on standard frontline chemotherapy and immunotherapy. We also saw it [added to] the National Comprehensive Cancer Network guidelines for [patients with IHC] 2+ and 3+ [disease]. It’s an exciting agent that is differentiated from how other agents, such as TKIs or chemotherapeutics, bind [to a target].”

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

In this OncClub episode, Branden Moriarity, PhD; and Beau Webber, PhD, both from the Masonic Cancer Center in Minneapolis, Minnesota, discussed the rationale and key findings from a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers.

“We…worked up a protocol to be able to take a process that had been developed for expanding TILs and adapt it to be able to incorporate the CRISPR editing,” Webber explained. “From an engineering standpoint, that took some optimization and creative thinking. We developed a process that worked efficiently in the early scale-up, but also throughout the trial. Our success and the ability to manufacture with these TILs from sick patients is impressive.”

“We in total treated 12 patients…and 50% of the patients achieved stable disease for up to 1 month post-therapy,” Moriarity reported. “All these patients had rapidly progressing disease, and [in] half of them, after treatment, their tumors stopped growing for a month.”

Check out the full OncClub subseries to see additional findings and insights from this research.

How Passion for Healing and Health Care Equity Expands Access to Innovative Therapies: With D. Ross Camidge, MD, PhD; and Brandon Blue, MD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by Brandon Blue, MD, a hematologist and oncologist at Moffitt Cancer Center in Tampa, Florida, to discuss Dr Blue’s path toward a career as a hematologic oncologist, focusing on his specialization in CAR T-cell therapy, his patient-centered approach to care, and the importance of institution-wide critical thinking to identify health care disparities and work to bridge these gaps.

“One of the big problems is that with any new innovation, you run the risk of having a new disparity,” Blue described. “All these cancer drugs were becoming available, but no one ever took a look in the rearview mirror and [asked]: Are the people who need them actually getting them? That for me was a big eye-opener.”

“Listening to you is inspiring,” Camidge said. “[Colleagues should] take your skills and the skills which have worked and somehow objectify them. You communicate in this way, you interact with your community and with your colleagues this way, and then you have to try and scale it. You have to prove it. You can’t just go: ‘It worked for me, and I’m great.’ I think you’re on the right path.”